X-Bolt Orthopedics announced the successful completion of the first US implant using its Pro-X1 Trochanteric Nailing System. This milestone marks the official commercial launch of the company’s flagship product.
The Pro-X1 system offers stronger anchorage and rotational stability in osteoporotic hip fracture fixation compared to traditional screw-based methods. This is especially beneficial for frail, elderly patients, as the expanding bolt provides superior fixation, addressing one of the major challenges in hip fracture treatment.
Pro-X1 builds on the company’s expanding bolt design, which was clinically proven in the largest-ever hip fracture randomized controlled trial, with the lowest-ever cut-out rate published for hip fractures at 0.8%.
Commenting on the milestone, Dr. Brian Thornes, X-Bolt’s founder and previous inventor of the globally recognized TightRope, said: “Orthopedic trauma has seen the treatment of ankle injuries revolutionized with the TightRope suture-button, and should expect to see a similar paradigm shift now in the treatment of hip fractures with our expanding bolt and the Pro-X1 system. Hip fractures affect over 200,000 patients annually in the U.S., and this will bring a much-needed advancement in patient care.”
The Pro-X1 Trochanteric Nailing System received FDA 510(k) clearance in 2023, and the completion of this first US surgery marks the beginning of a limited commercial release. X-Bolt plans to scale its operations in the coming months, deploying additional inventory and expanding its reach to more markets across the United States.
X-Bolt Orthopedics announced the successful completion of the first US implant using its Pro-X1 Trochanteric Nailing System. This milestone marks the official commercial launch of the company's flagship product.
The Pro-X1 system offers stronger anchorage and rotational stability in osteoporotic hip fracture fixation compared to traditional...
X-Bolt Orthopedics announced the successful completion of the first US implant using its Pro-X1 Trochanteric Nailing System. This milestone marks the official commercial launch of the company’s flagship product.
The Pro-X1 system offers stronger anchorage and rotational stability in osteoporotic hip fracture fixation compared to traditional screw-based methods. This is especially beneficial for frail, elderly patients, as the expanding bolt provides superior fixation, addressing one of the major challenges in hip fracture treatment.
Pro-X1 builds on the company’s expanding bolt design, which was clinically proven in the largest-ever hip fracture randomized controlled trial, with the lowest-ever cut-out rate published for hip fractures at 0.8%.
Commenting on the milestone, Dr. Brian Thornes, X-Bolt’s founder and previous inventor of the globally recognized TightRope, said: “Orthopedic trauma has seen the treatment of ankle injuries revolutionized with the TightRope suture-button, and should expect to see a similar paradigm shift now in the treatment of hip fractures with our expanding bolt and the Pro-X1 system. Hip fractures affect over 200,000 patients annually in the U.S., and this will bring a much-needed advancement in patient care.”
The Pro-X1 Trochanteric Nailing System received FDA 510(k) clearance in 2023, and the completion of this first US surgery marks the beginning of a limited commercial release. X-Bolt plans to scale its operations in the coming months, deploying additional inventory and expanding its reach to more markets across the United States.
Copy to clipboard 
